Search results for " Primary"

showing 10 items of 453 documents

Associations between single-nucleotide polymorphisms of the VEGF gene and long-term prognosis of oral squamous cell carcinoma.

2012

Department of Otorhinolaryngology, Johannes Gutenberg-University, Mainz, GermanyINTRODUCTION: Functional polymorphisms (SNPs) ofthe vascular endothelial growth factor (VEGF) are asso-ciated with the incidence of oral squamous cell carcinoma(OSCC). An impact of VEGF-SNPs on prognosis of OSCCpatients seems possible. Therefore, correlations betweenprognostic parameters of OSCC patients and five VEGF-SNPs were determined.MATERIALS AND METHODS: In a retrospective long-term study, in 113 OSCC patients that underwentcurative resections, five VEGF-SNPs ( 1154 G/A,+405 G/C, +936 C/T, 2578 C/A, and 460 C/T) wereanalyzed. Associations between SNPs and prognosis(incidence of local recurrent disease, seco…

OncologyMaleVascular Endothelial Growth Factor ACancer ResearchAdenosinechemistry.chemical_compoundGene FrequencyPolymorphism (computer science)Longitudinal StudiesAged 80 and overIncidence (epidemiology)SmokingNeoplasms Second PrimaryMiddle AgedPrognosisVascular endothelial growth factorSurvival RateCarcinoma Squamous CellPeriodonticsBiomarker (medicine)FemaleMouth NeoplasmsOral SurgeryAdultmedicine.medical_specialtyGuanineGenotypeSingle-nucleotide polymorphismPolymorphism Single NucleotideDisease-Free SurvivalPathology and Forensic MedicineCytosineYoung AdultInternal medicinemedicineCarcinomaHumansSurvival rateAgedNeoplasm StagingRetrospective Studiesbusiness.industryHaplotypemedicine.diseasestomatognathic diseasesOtorhinolaryngologychemistryHaplotypesNeoplasm Recurrence LocalbusinessThymineFollow-Up StudiesJournal of oral pathologymedicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology
researchProduct

Patterns of Prior and Subsequent Neoplasms in Children and Adolescents With Soft Tissue Sarcomas.

2020

Background The occurrence of prior, concurrent and subsequent neoplasms (SN) represents a serious problem in children and adolescents with soft tissue sarcomas. Pathogenic germline variants contribute to the diagnosis of multiple neoplasms in sarcoma survivors. Materials and methods The records of 748 children and adolescents, diagnosed with soft tissue sarcomas and registered in trials/registries by the cooperative soft tissue sarcoma (Cooperative Weichteilsarkom Studie) group, were reviewed for the occurrence of SNs. Reference histology review was available for all cases; the presence of oncogenic fusions known at the time of diagnosis was confirmed for fusion-positive (F+) entities. Resu…

OncologyMalemedicine.medical_specialtyAdolescentOncogene Proteins FusionGermline03 medical and health sciences0302 clinical medicineCancer SurvivorsRisk FactorsInternal medicineGermanyBiomarkers TumorMedicineHumansRegistriesNeurofibromatosisChildGerm-Line MutationClinical Trials as Topicbusiness.industryIncidence (epidemiology)Soft tissue sarcomaIncidenceSoft tissueInfantHistologyNeoplasms Second PrimarySarcomaHematologymedicine.diseasePrognosisCombined Modality TherapySurvival RateOncology030220 oncology & carcinogenesisChild PreschoolPediatrics Perinatology and Child HealthFemaleSarcomabusiness030215 immunologyFollow-Up StudiesJournal of pediatric hematology/oncology
researchProduct

Epidemiology and prognosis of synchronous and metachronous colon cancer metastases: a French population-based study.

2014

Epidemiological data on synchronous and metachronous metastatic colon cancer are scarce. We assessed epidemiological characteristics and survival in synchronous and metachronous metastatic colon cancer in a French population.Our study included 932 cases of metastatic colon cancer diagnosed in 1999-2010 and registered in a population-based cancer registry; 758 were synchronous colon metastases and 174 metachronous metastases from resected primary colon cancers diagnosed in 1999-2005. Univariate relative survival was calculated and a multivariate model with proportional hazard applied to net survival by interval was used.Mean age at diagnosis was 71.1 years for patients with metachronous meta…

OncologyMalemedicine.medical_specialtyColorectal cancermedicine.medical_treatmentPopulationNeoplasms Multiple PrimaryMetachronous metastasisRisk FactorsInternal medicineEpidemiologyMedicineHumanseducationAgedRetrospective StudiesChemotherapyeducation.field_of_studyHepatologyRelative survivalbusiness.industryGastroenterologyNeoplasms Second PrimaryOdds ratiomedicine.diseasePrognosisCancer registrySurvival RatePopulation SurveillanceColonic NeoplasmsFemaleFranceMorbiditybusinessFollow-Up StudiesDigestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
researchProduct

Secondary acute leukemia following mitoxantrone-based high-dose chemotherapy for primary breast cancer patients.

2003

The incidence of secondary myelodysplasia/acute myeloid leukemia (AML) was retrospectively assessed in an international joint study in 305 node-positive breast cancer patients, who received mitoxantrone-based high-dose chemotherapy (HDCT) followed by autologous stem cell support as adjuvant therapy. The median age of the patients was 57 years (range 22-67). In all, 268 patients received peripheral blood stem cells, and 47 patients received autologous bone marrow. After a median follow-up of 57 months (range 10-125), three cases of secondary AML (sAML) were observed, resulting in a cumulative incidence of 0.94%. One case of sAML developed 18 months after HDCT (FAB M3) The karyotype was trans…

OncologyTransplantation Conditioningmedicine.medical_treatmentAutologous stem-cell transplantationLeukemia Promyelocytic Acutehemic and lymphatic diseasesAntineoplastic Combined Chemotherapy ProtocolsMelphalanBone Marrow TransplantationLeukemia Radiation-InducedAcute leukemiaIncidenceCytarabineNeoplasms Second PrimaryHematologyMiddle AgedCombined Modality TherapyLeukemia MyeloidLymphatic MetastasisAcute DiseaseFemalemedicine.drugAdultmedicine.medical_specialtyPaclitaxelBreast NeoplasmsTransplantation AutologousLeukemia Myelomonocytic AcuteBreast cancerInternal medicinemedicineAdjuvant therapyHumansCyclophosphamideAgedEpirubicinTransplantationChemotherapyMitoxantronePeripheral Blood Stem Cell Transplantationbusiness.industryDaunorubicinmedicine.diseaseSurgeryRadiation therapyTransplantationDoxorubicinRadiotherapy AdjuvantMitoxantronebusinessThiotepaBone marrow transplantation
researchProduct

Survival after curative pelvic exenteration for primary or recurrent cervical cancer a retrospective multicentric study of 167 patients

2014

ObjectiveEvaluate the survival of patients who underwent pelvic exenteration (PE) with curative intent for primary persistent or recurrent cervical cancer.MethodsWe retrospectively investigated 167 consecutive patients, referred to the gynecological oncology units of 4 centers in Germany or Italy, who underwent PE. Data regarding surgery, histology, and oncologic outcomes were collected and statistically evaluated. Survival was determined from the day of exenteration until last follow-up or death.ResultsThe median age was 51 years. Twenty-seven patients (16.2%) underwent PE owing to advanced primary tumors (group A), 34 patients (20.4%) underwent PE owing to persistent cancer after chemothe…

OncologyUterine Cervical NeoplasmSurvivalmedicine.medical_treatmentUterine Cervical NeoplasmsRetrospective StudieLymph nodeCervical cancerAged 80 and overMedicine (all)Obstetrics and GynecologyMiddle AgedPrognosisCombined Modality TherapySurvival Ratemedicine.anatomical_structureOncologyLymphatic MetastasisCarcinoma Squamous CellAdenocarcinomaFemaleHumanAdultmedicine.medical_specialtyPrognosiAdenocarcinomaFollow-Up StudieYoung AdultInternal medicinemedicineCarcinomaHumansSurvival pelvic exenteration primary recurrent cervical cancerSurvival rateRetrospective StudiesAgedNeoplasm StagingPelvic exenterationbusiness.industryCancerRetrospective cohort studyLymphatic Metastasimedicine.diseaseSurgeryPelvic ExenterationSettore MED/40 - GINECOLOGIA E OSTETRICIACervical cancerNeoplasm Recurrence LocalbusinessFollow-Up Studies
researchProduct

Second malignancies after treatment of childhood non-Hodgkin lymphoma: a report of the Berlin-Frankfurt-Muenster study group

2021

Haematologica : journal of the European Hematology Association 106(5), 1390-1400 (2021). doi:10.3324/haematol.2019.244780

Oncologymedicine.medical_specialtyArticle03 medical and health sciences0302 clinical medicineRisk FactorsInternal medicinemedicineHumansCumulative incidence030304 developmental biology0303 health sciencesChildhood Cancer RegistryUnivariate analysisbusiness.industryIncidenceLymphoma Non-HodgkinMyelodysplastic syndromesIncidence (epidemiology)Lymphoblastic lymphomaMyeloid leukemiaNeoplasms Second PrimaryHematologyPrecursor Cell Lymphoblastic Leukemia-Lymphomamedicine.diseaseLymphoma030220 oncology & carcinogenesisFemaleCranial Irradiationbusiness
researchProduct

Assessment of the frequency of additional cancers in patients with splenic marginal zone lymphoma

2006

Abstract: Objectives: Solid second primary cancers (SPC) have become an issue of extensive research. The purpose of the present study was to estimate the standardised incidence ratio (SIR) and the absolute excess risk (AER) of SPC in patients with splenic marginal zone lymphoma (SMZL). Methods: We investigated the incidence of additional cancers in 129 patients consecutively diagnosed with SMZL in three Italian haematological centres, asking the cooperating doctors for additional information on initial and subsequent therapies and on the onset and type of second cancers. Results: Twelve SPC were recorded (9.3%); the 3- and 5-yr cumulative incidence rates were 5.5% and 18.3% respectively, wi…

Oncologymedicine.medical_specialtyLymphomaPopulationsplenic marginal zone lymphomaBreast cancerInternal medicinemedicinecancerHumansCumulative incidenceSplenic marginal zone lymphomaLung cancereducationAgededucation.field_of_studysplenic marginal zone lymphoma cancerbusiness.industryIncidenceSplenic Neoplasmsadditional cancerCancerNeoplasms Second PrimarySplenic lymphoma with villous lymphocytesHematologyGeneral MedicineMiddle Agedmedicine.diseaseNon-Hodgkin's lymphomabusinessEuropean Journal of Haematology
researchProduct

The Assessment of Second Primary Cancers (SPCs) in a Series of Splenic Marginal Zone Lymphoma (SMZL) Patients

2006

The purpose of this study is to estimate the risk of second primary cancer (SPC) in 129 consecutive patients with splenic marginal zone lymphoma (SMZL) diagnosed in three Italian haematological centres. The person-years method deriving as a sum of products of age- and sex- specific rates and of the corresponding time at risk was used. The SPC Standardized Incidence Ratio (SIR) was 2.03 with a 95% confidence interval: [1.05, 3.56] (p < 0.05) and the corresponding Absolute Excess Risk (AER) was 145.8 (per 10000 SMZL patients per year). Our findings evidence a high frequency of additional cancers in patients with SMZL and suggest that the incidence rate of SPCs is significantly different from …

Oncologymedicine.medical_specialtyeducation.field_of_studySeries (stratigraphy)business.industryPopulationAbsolute risk reductionmedicine.diseaseSecond Primary CancersConfidence intervalStandardized mortality ratioTime at riskInternal medicinemedicineSplenic marginal zone lymphomaeducationbusiness
researchProduct

Human brain organoids assemble functionally integrated bilateral optic vesicles

2021

During embryogenesis, optic vesicles develop from the diencephalon via a multistep process of organogenesis. Using induced pluripotent stem cell (iPSC)-derived human brain organoids, we attempted to simplify the complexities and demonstrate formation of forebrain-associated bilateral optic vesicles, cellular diversity, and functionality. Around day 30, brain organoids attempt to assemble optic vesicles, which develop progressively as visible structures within 60 days. These optic vesicle-containing brain organoids (OVB-organoids) constitute a developing optic vesicle's cellular components, including primitive corneal epithelial and lens-like cells, retinal pigment epithelia, retinal progeni…

OrganogenesisInduced Pluripotent Stem Cellsretinal pigment epitheliumiPSCsEmbryonic DevelopmentBiology03 medical and health sciencesDiencephalonchemistry.chemical_compoundProsencephalon0302 clinical medicineGeneticsOrganoidmedicineHumansInduced pluripotent stem cell030304 developmental biology0303 health sciencesforebrain organoidsRetinal pigment epitheliumbrain organoidsVesicleprimordial eye fieldsOVB-organoidsCell DifferentiationRetinalCell BiologyOptic vesicleHuman brainCell biologyOrganoidsmedicine.anatomical_structurenervous systemchemistryMolecular MedicineFOXG1; OVB-organoids; brain organoids; forebrain organoids; iPSCs; optic vesicles; primary cilium; primordial eye fields; retinal pigment epitheliumoptic vesiclesFOXG1030217 neurology & neurosurgeryprimary ciliumCell Stem Cell
researchProduct

Spinal tumours : recommendations of the Polish Society of Spine Surgery, the Polish Society of Oncology, the Polish Society of Neurosurgeons, the Pol…

2023

Abstract Purpose The purpose of these recommendations is to spread the available evidence for evaluating and managing spinal tumours among clinicians who encounter such entities. Methods The recommendations were developed by members of the Development Recommendations Group representing seven stakeholder scientific societies and organizations of specialists involved in various forms of care for patients with spinal tumours in Poland. The recommendations are based on data yielded from systematic reviews of the literature identified through electronic database searches. The strength of the recommendations was graded according to the North American Spine Society’s grades of recommendation for s…

Orthopedics and Sports MedicineSurgeryBenign primary spinal tumours; Multidisciplinary management of spinal tumours; Primary malignant spinal tumours; Sarcoma; Spinal metastases
researchProduct